Pentoxifylline html Perindopril | Perinev tablets 4 mg, 90 pcs.
Special Price
$24.25
Regular Price
$33.00
In stock
SKU
BID466303
https://www.piluli.ru/product461848/product_info.html Release form
Tablets.
Tablets.
https://www.piluli.ru/product461848/product_info.html Release form
Tablets.
Packing
90 pcs.
https://www.piluli.ru/product461848/product_info.html Pharmacological action of
Perineva - an ACE inhibitor, or kininase II, refers to oxopeptidases. It converts angiotensin I into a vasoconstrictor angiotensin II and destroys the bradykinin vasodilator to an inactive hectapeptide. Suppression of ACE activity leads to a decrease in the level of angiotensin II and an increase in plasma renin activity (suppressing the negative feedback of renin release) and a decrease in aldosterone secretion. Since ACE also destroys bradykinin, suppression of ACE also leads to an increase in the activity of the circulating and tissue kallikrein-kinin system, while the prostaglandin system is activated. Perindopril has a therapeutic effect due to the active metabolite - perindoprilat. Perindopril reduces both systolic and diastolic blood pressure in the supine and standing position. Perindopril reduces OPSS, which leads to a decrease in blood pressure. In this case, peripheral blood flow is accelerated. However, heart rate does not increase. Renal blood flow tends to increase, while glomerular filtration rate does not change. The maximum antihypertensive effect is achieved 4-6 hours after a single dose. The antihypertensive effect persists for 24 hours, and after 24 hours the drug still provides from 87% to 100% of the maximum effect. A decrease in blood pressure develops rapidly. Stabilization of the antihypertensive effect is observed after 1 month of therapy and persists for a long time. Discontinuation of therapy is not accompanied by withdrawal syndrome. Perindopril reduces left ventricular myocardial hypertrophy. With prolonged use reduces the severity of interstitial fibrosis, normalizes the isoenzyme profile of myosin. It increases the concentration of HDL, in patients with hyperuricemia it decreases the concentration of uric acid. Perindopril improves the elasticity of large arteries, eliminates structural changes in small arteries. Perindopril normalizes the functioning of the heart, reducing pre- and afterload. In patients with chronic heart failure treated with perindopril, the following was noted: a decrease in filling pressure in the left and right ventricles, a decrease in heart rate, an increase in cardiac output and cardiac index. Taking the initial dose of perindopril 2 mg in patients with chronic heart failure I-II functional class according to NYHA classification was not accompanied by a statistically significant decrease in blood pressure compared with placebo.
Indications
Arterial hypertension.
Chronic heart failure.
Prevention of re-stroke (as part of complex therapy with indapamide) in patients with a history of cerebrovascular disease (stroke or transient cerebral ischemic attack).
Stable coronary heart disease: reduced risk of developing cardiovascular complications in patients who have previously had myocardial infarction and / or coronary revascularization.
https://www.piluli.ru/product461848/product_info.html Contraindications
History of angioedema (hereditary, idiopathic or angioedema due to ACE inhibitors).
Age under 18 years (efficacy and safety not established).
Hereditary galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption syndrome.
Hypersensitivity to the drug.
Hypersensitivity to other ACE inhibitors.
https://www.piluli.ru/product461848/product_info.html Use during pregnancy and lactation
In pregnancy, the use of the drug is contraindicated. When pregnancy is confirmed, Perinev's drug must be canceled as soon as possible. The use in the II and III trimesters of pregnancy can cause fetotoxic effects (decreased renal function, oligohydramnios, slowing down the ossification of the bones of the skull of the fetus) and neonatal toxic effects (renal failure, arterial hypotension, hyperkalemia). In the case of using the drug in the II and III trimesters of pregnancy, it is necessary to conduct an ultrasound examination of the kidneys and bones of the fetal skull. The use of the drug Perineva during lactation is not recommended, due to the lack of data on the possibility of perindopril penetration into breast milk. If it is necessary to use the drug during lactation, breastfeeding should be discontinued.
Composition
Active ingredient: perindopril erbumin 4 mg.
Excipients of prefabricated granules: calcium chloride hexahydrate, lactose monohydrate, crospovidone.
Excipients: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.
https://www.piluli.ru/product461848/product_info.html Dosing and Administration
Inside, it is recommended to take 1 time per day, before meals, preferably in the morning.
The dose of the drug is selected individually for each patient, depending on the severity of the disease and individual response to treatment.
The drug Perinev can be used in monotherapy and in combination with other antihypertensive drugs.
The recommended starting dose is 4 mg once daily in the morning. For patients with severe activation of the renin-angiotensin-aldosterone system (for example, with renovascular hypertension, hypovolemia and / or hyponatremia, CHF in the stage of decompensation or severe arterial hypertension), the recommended initial dose is 2 mg / day in one dose. If therapy is ineffective for a month, the dose can be increased to 8 mg once a day and with good tolerance to the previous dose.
https://www.piluli.ru/product461848/product_info.html Side effects
Classification of the frequency of side effects (WHO): very often -> 1/10 often - from> 1/100 to 1/1000 to 1 / 10000 to From the central and peripheral nervous system: often - headache, dizziness, paresthesia sometimes - sleep or mood disorders are very rare - confusion.
From the side of the organ of vision: often - visual impairment.
On the part of the hearing organ: often - tinnitus.
From the cardiovascular system: often - a marked decrease in blood pressure is very rare - arrhythmias, angina pectoris, myocardial infarction or stroke, possibly secondary, due to severe arterial hypotension in patients at high risk for vasculitis (frequency unknown).
On the part of the respiratory system: often - cough, shortness of breath sometimes - bronchospasm is very rare - eosinophilic pneumonia, rhinitis.
From the digestive tract: often - nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, diarrhea, constipation, sometimes - dry oral mucosa rarely - pancreatitis very rarely - cytolytic or cholestatic hepatitis.
From the skin: often - a skin rash, itching sometimes - angioedema of the face, limbs, urticaria, very rarely - erythema multiforme.
From the musculoskeletal system: often - muscle cramps.
From the genitourinary system: sometimes - renal failure, impotence is very rare - acute renal failure.
General disorders: often - asthenia sometimes - increased sweating.
Hematopoietic and lymphatic organs: very rare - with prolonged use at high doses, hemoglobin and hematocrit concentrations, thrombocytopenia, leukopenia / neutropenia, agranulocytosis, pancytopenia are very rare - hemolytic anemia (in patients with congenital glucose-6-phosphate deficiency) )
Lab performance: an increase in the concentration of urea in blood serum and plasma creatinine and hyperkalemia, reversible after discontinuation of the drug (especially in patients with renal failure, severe heart failure and renovascular hypertension) rarely - increased activity of liver enzymes and bilirubin in blood serum hypoglycemia.
https://www.piluli.ru/product461848/product_info.html Drug Interactions
Patients taking diuretics, especially with excessive excretion of fluid and / or sodium, may develop excessive arterial hypotension at the beginning of treatment with ACE inhibitors. The risk of developing excessive arterial hypotension can be reduced by discontinuing the diuretic, intravenous administration of 0.9% sodium chloride solution, and also by setting an ACE inhibitor at lower doses. A further increase in the dose of perindopril should be carried out with caution. Usually, with serum ACE inhibitor therapy, the serum potassium concentration remains within normal limits, but some patients may develop hyperkalemia. The combined use of ACE inhibitors and potassium-sparing diuretics (for example, spironolactone, triamteren or amiloride), potassium preparations or potassium-containing products and food additives can cause hyperkalemia. Therefore, it is not recommended to combine perindopril with these drugs. These combinations should be prescribed only in case of hypokalemia, observing safety precautions and regularly monitoring the concentration of potassium ions in the blood serum. With the simultaneous use of lithium preparations and ACE inhibitors, the development of a reversible increase in serum lithium concentrations and lithium toxicity is possible. With the simultaneous use of ACE inhibitors with thiazide diuretics, it is possible to further increase the concentration of lithium in blood serum and increase the risk of its toxic effects. The simultaneous use of perindopril and lithium is not recommended. If necessary, such combination therapy is carried out under regular monitoring of the concentration of lithium in blood serum. NSAID therapy may attenuate the antihypertensive effect of ACE inhibitors. In addition, NSAIDs and ACE inhibitors have an additive effect on increasing the concentration of potassium ions in the blood serum, which can cause a deterioration in kidney function. This effect is usually reversible. In rare cases, acute renal failure may develop, especially in patients with pre-existing renal impairment, for example, in elderly patients or against the background of dehydration. With the simultaneous use of perindopril with other antihypertensive agents, it is possible to enhance the antihypertensive effect of perindopril. The simultaneous use of nitroglycerin, other nitrates or vasodilators can lead to an additional hypotensive effect. The simultaneous use of ACE inhibitors and hypoglycemic agents (insulin or hypoglycemic agents for oral administration) can enhance the hypoglycemic effect, up to the development of hypoglycemia. As a rule, this phenomenon occurs in the first weeks of combination therapy in patients with renal failure. Perindopril can be combined with acetylsalicylic acid (as an antiplatelet agent), thrombolytic agents and beta-blockers and / or nitrates. Joint use with ACE inhibitors can lead to an increase in the hypotensive effect. Sympathomimetics can weaken the antihypertensive effect of ACE inhibitors. In the appointment of such a combination should regularly evaluate the effectiveness of ACE inhibitors.
https://www.piluli.ru/product461848/product_info.html Overdose
Symptoms: marked decrease in blood pressure, shock, disturbances of the water-electrolyte balance (hyperkalemia, hyponatremia), renal failure, hyperventilation, heart disease, tachycardia, tachycardia, tachycardia, , anxiety, cough.
Treatment: with a marked decrease in blood pressure - give the patient a horizontal position with raised legs and take measures to replenish the bcc, if possible - in / in the introduction of angiotensin II and / or in / in the introduction of catecholamines. With the development of severe bradycardia, not amenable to drug therapy (including atropine), The installation of an artificial pacemaker (pacemaker) is shown. It is necessary to control the vital functions and serum creatinine and electrolytes. Perindopril can be removed from the systemic circulation by hemodialysis. The use of high flow polyacrylonitrile membranes must be avoided.
Storage conditions
Do not store above 30 РC.
Active ingredient
Paracetamol, html Deystvuyuschee substances
Perindopril
https://www.piluli.ru/prod uct461848 / product_info. html Form of Treatment
tablets
https://www.piluli.ru/product461848/product_info.html KRKA d.d. Novo mesto AO, Slovenia
Tablets.
Packing
90 pcs.
https://www.piluli.ru/product461848/product_info.html Pharmacological action of
Perineva - an ACE inhibitor, or kininase II, refers to oxopeptidases. It converts angiotensin I into a vasoconstrictor angiotensin II and destroys the bradykinin vasodilator to an inactive hectapeptide. Suppression of ACE activity leads to a decrease in the level of angiotensin II and an increase in plasma renin activity (suppressing the negative feedback of renin release) and a decrease in aldosterone secretion. Since ACE also destroys bradykinin, suppression of ACE also leads to an increase in the activity of the circulating and tissue kallikrein-kinin system, while the prostaglandin system is activated. Perindopril has a therapeutic effect due to the active metabolite - perindoprilat. Perindopril reduces both systolic and diastolic blood pressure in the supine and standing position. Perindopril reduces OPSS, which leads to a decrease in blood pressure. In this case, peripheral blood flow is accelerated. However, heart rate does not increase. Renal blood flow tends to increase, while glomerular filtration rate does not change. The maximum antihypertensive effect is achieved 4-6 hours after a single dose. The antihypertensive effect persists for 24 hours, and after 24 hours the drug still provides from 87% to 100% of the maximum effect. A decrease in blood pressure develops rapidly. Stabilization of the antihypertensive effect is observed after 1 month of therapy and persists for a long time. Discontinuation of therapy is not accompanied by withdrawal syndrome. Perindopril reduces left ventricular myocardial hypertrophy. With prolonged use reduces the severity of interstitial fibrosis, normalizes the isoenzyme profile of myosin. It increases the concentration of HDL, in patients with hyperuricemia it decreases the concentration of uric acid. Perindopril improves the elasticity of large arteries, eliminates structural changes in small arteries. Perindopril normalizes the functioning of the heart, reducing pre- and afterload. In patients with chronic heart failure treated with perindopril, the following was noted: a decrease in filling pressure in the left and right ventricles, a decrease in heart rate, an increase in cardiac output and cardiac index. Taking the initial dose of perindopril 2 mg in patients with chronic heart failure I-II functional class according to NYHA classification was not accompanied by a statistically significant decrease in blood pressure compared with placebo.
Indications
Arterial hypertension.
Chronic heart failure.
Prevention of re-stroke (as part of complex therapy with indapamide) in patients with a history of cerebrovascular disease (stroke or transient cerebral ischemic attack).
Stable coronary heart disease: reduced risk of developing cardiovascular complications in patients who have previously had myocardial infarction and / or coronary revascularization.
https://www.piluli.ru/product461848/product_info.html Contraindications
History of angioedema (hereditary, idiopathic or angioedema due to ACE inhibitors).
Age under 18 years (efficacy and safety not established).
Hereditary galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption syndrome.
Hypersensitivity to the drug.
Hypersensitivity to other ACE inhibitors.
https://www.piluli.ru/product461848/product_info.html Use during pregnancy and lactation
In pregnancy, the use of the drug is contraindicated. When pregnancy is confirmed, Perinev's drug must be canceled as soon as possible. The use in the II and III trimesters of pregnancy can cause fetotoxic effects (decreased renal function, oligohydramnios, slowing down the ossification of the bones of the skull of the fetus) and neonatal toxic effects (renal failure, arterial hypotension, hyperkalemia). In the case of using the drug in the II and III trimesters of pregnancy, it is necessary to conduct an ultrasound examination of the kidneys and bones of the fetal skull. The use of the drug Perineva during lactation is not recommended, due to the lack of data on the possibility of perindopril penetration into breast milk. If it is necessary to use the drug during lactation, breastfeeding should be discontinued.
Composition
Active ingredient: perindopril erbumin 4 mg.
Excipients of prefabricated granules: calcium chloride hexahydrate, lactose monohydrate, crospovidone.
Excipients: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.
https://www.piluli.ru/product461848/product_info.html Dosing and Administration
Inside, it is recommended to take 1 time per day, before meals, preferably in the morning.
The dose of the drug is selected individually for each patient, depending on the severity of the disease and individual response to treatment.
The drug Perinev can be used in monotherapy and in combination with other antihypertensive drugs.
The recommended starting dose is 4 mg once daily in the morning. For patients with severe activation of the renin-angiotensin-aldosterone system (for example, with renovascular hypertension, hypovolemia and / or hyponatremia, CHF in the stage of decompensation or severe arterial hypertension), the recommended initial dose is 2 mg / day in one dose. If therapy is ineffective for a month, the dose can be increased to 8 mg once a day and with good tolerance to the previous dose.
https://www.piluli.ru/product461848/product_info.html Side effects
Classification of the frequency of side effects (WHO): very often -> 1/10 often - from> 1/100 to 1/1000 to 1 / 10000 to From the central and peripheral nervous system: often - headache, dizziness, paresthesia sometimes - sleep or mood disorders are very rare - confusion.
From the side of the organ of vision: often - visual impairment.
On the part of the hearing organ: often - tinnitus.
From the cardiovascular system: often - a marked decrease in blood pressure is very rare - arrhythmias, angina pectoris, myocardial infarction or stroke, possibly secondary, due to severe arterial hypotension in patients at high risk for vasculitis (frequency unknown).
On the part of the respiratory system: often - cough, shortness of breath sometimes - bronchospasm is very rare - eosinophilic pneumonia, rhinitis.
From the digestive tract: often - nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, diarrhea, constipation, sometimes - dry oral mucosa rarely - pancreatitis very rarely - cytolytic or cholestatic hepatitis.
From the skin: often - a skin rash, itching sometimes - angioedema of the face, limbs, urticaria, very rarely - erythema multiforme.
From the musculoskeletal system: often - muscle cramps.
From the genitourinary system: sometimes - renal failure, impotence is very rare - acute renal failure.
General disorders: often - asthenia sometimes - increased sweating.
Hematopoietic and lymphatic organs: very rare - with prolonged use at high doses, hemoglobin and hematocrit concentrations, thrombocytopenia, leukopenia / neutropenia, agranulocytosis, pancytopenia are very rare - hemolytic anemia (in patients with congenital glucose-6-phosphate deficiency) )
Lab performance: an increase in the concentration of urea in blood serum and plasma creatinine and hyperkalemia, reversible after discontinuation of the drug (especially in patients with renal failure, severe heart failure and renovascular hypertension) rarely - increased activity of liver enzymes and bilirubin in blood serum hypoglycemia.
https://www.piluli.ru/product461848/product_info.html Drug Interactions
Patients taking diuretics, especially with excessive excretion of fluid and / or sodium, may develop excessive arterial hypotension at the beginning of treatment with ACE inhibitors. The risk of developing excessive arterial hypotension can be reduced by discontinuing the diuretic, intravenous administration of 0.9% sodium chloride solution, and also by setting an ACE inhibitor at lower doses. A further increase in the dose of perindopril should be carried out with caution. Usually, with serum ACE inhibitor therapy, the serum potassium concentration remains within normal limits, but some patients may develop hyperkalemia. The combined use of ACE inhibitors and potassium-sparing diuretics (for example, spironolactone, triamteren or amiloride), potassium preparations or potassium-containing products and food additives can cause hyperkalemia. Therefore, it is not recommended to combine perindopril with these drugs. These combinations should be prescribed only in case of hypokalemia, observing safety precautions and regularly monitoring the concentration of potassium ions in the blood serum. With the simultaneous use of lithium preparations and ACE inhibitors, the development of a reversible increase in serum lithium concentrations and lithium toxicity is possible. With the simultaneous use of ACE inhibitors with thiazide diuretics, it is possible to further increase the concentration of lithium in blood serum and increase the risk of its toxic effects. The simultaneous use of perindopril and lithium is not recommended. If necessary, such combination therapy is carried out under regular monitoring of the concentration of lithium in blood serum. NSAID therapy may attenuate the antihypertensive effect of ACE inhibitors. In addition, NSAIDs and ACE inhibitors have an additive effect on increasing the concentration of potassium ions in the blood serum, which can cause a deterioration in kidney function. This effect is usually reversible. In rare cases, acute renal failure may develop, especially in patients with pre-existing renal impairment, for example, in elderly patients or against the background of dehydration. With the simultaneous use of perindopril with other antihypertensive agents, it is possible to enhance the antihypertensive effect of perindopril. The simultaneous use of nitroglycerin, other nitrates or vasodilators can lead to an additional hypotensive effect. The simultaneous use of ACE inhibitors and hypoglycemic agents (insulin or hypoglycemic agents for oral administration) can enhance the hypoglycemic effect, up to the development of hypoglycemia. As a rule, this phenomenon occurs in the first weeks of combination therapy in patients with renal failure. Perindopril can be combined with acetylsalicylic acid (as an antiplatelet agent), thrombolytic agents and beta-blockers and / or nitrates. Joint use with ACE inhibitors can lead to an increase in the hypotensive effect. Sympathomimetics can weaken the antihypertensive effect of ACE inhibitors. In the appointment of such a combination should regularly evaluate the effectiveness of ACE inhibitors.
https://www.piluli.ru/product461848/product_info.html Overdose
Symptoms: marked decrease in blood pressure, shock, disturbances of the water-electrolyte balance (hyperkalemia, hyponatremia), renal failure, hyperventilation, heart disease, tachycardia, tachycardia, tachycardia, , anxiety, cough.
Treatment: with a marked decrease in blood pressure - give the patient a horizontal position with raised legs and take measures to replenish the bcc, if possible - in / in the introduction of angiotensin II and / or in / in the introduction of catecholamines. With the development of severe bradycardia, not amenable to drug therapy (including atropine), The installation of an artificial pacemaker (pacemaker) is shown. It is necessary to control the vital functions and serum creatinine and electrolytes. Perindopril can be removed from the systemic circulation by hemodialysis. The use of high flow polyacrylonitrile membranes must be avoided.
Storage conditions
Do not store above 30 РC.
Active ingredient
Paracetamol, html Deystvuyuschee substances
Perindopril
https://www.piluli.ru/prod uct461848 / product_info. html Form of Treatment
tablets
https://www.piluli.ru/product461848/product_info.html KRKA d.d. Novo mesto AO, Slovenia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review